Glycosaminoglycan Therapy for Bladder Diseases: Emerging New Treatments Pier Francesco Bassi, Elisabetta Costantini, Steve Foley, Stefano Palea European.

Slides:

Advertisements

Similar presentations

Volume 50, Issue 3, Pages (September 2006)

Advertisements

Pascal Rischmann European Urology Supplements

Recurrent Urinary Tract Infections: Uro-Vaxom®, a New Alternative

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Recurrent Urinary Tract Infections: Uro-Vaxom®, a New Alternative

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Management of Acute and Chronic Retention in Men

Tet Yap, Nicholas Watkin, Suks Minhas European Urology Supplements

Volume 59, Issue 4, Pages (April 2011)

Shock Wave Lithotripsy for Renal and Ureteric Stones

Bladder Cancer: Management and Future Directions

Shock Wave Lithotripsy for Renal and Ureteric Stones

Volume 63, Issue 1, Pages (January 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

R. Colodner, O. Nitzan, B. Chazan, H. Edelstein, R. Raz

Bladder Cancer: A Major Public Health Issue

Volume 47, Issue 2, Pages (February 2005)

Back to the Future: Introduction and Conclusions

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Volume 64, Issue 4, Pages (October 2013)

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Volume 49, Issue 6, Pages (June 2006)

Functional Bladder Problems

Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old P. Perrin,

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Richard C. Harkaway European Urology Supplements

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Volume 74, Issue 5, Pages (November 2018)

Philip Toozs-Hobson, Pallavi Latthe European Urology Supplements

Ian Milsom European Urology Supplements

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Jacques Irani European Urology Supplements

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

Rotavirus vaccination: a concise review

Long-Term Hormonal Therapy: Who Would Benefit?

Bladder Cancer: Highlights from 2006

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Pharmacotherapy in Stress and Mixed Incontinence

Christian Stief European Urology Supplements

European Urology is “Your” Journal

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

New Trends in Managing the Prostate Cancer Patient

Emmanuel Chartier-Kastler, Kate Davidson European Urology Supplements

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Martin Michel, Jean de la Rosette European Urology Supplements

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus, P. Teillac

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Axel Heidenreich European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

The Burden of Stress Urinary Incontinence

Profile of Silodosin European Urology Supplements

Volume 52, Issue 4, Pages (October 2007)

New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men

Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events J. Alfred Witjes, Joan Palou, Mark.

LUTS and Sexual Dysfunction: Implications for Management of BPH

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Testim® Gel: Review of Clinical Data

Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects Martin C. Michel, Cees Korstanje, Walter.

C.G Roehrborn, T McNicholas European Urology Supplements

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Classification of Mixed Incontinence

Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Axel Heidenreich European Urology Supplements

Michael Marberger European Urology Supplements

Presentation transcript:

Glycosaminoglycan Therapy for Bladder Diseases: Emerging New Treatments Pier Francesco Bassi, Elisabetta Costantini, Steve Foley, Stefano Palea European Urology Supplements Volume 10, Issue 6, Pages 451-459 (October 2011) DOI: 10.1016/j.eursup.2011.06.001 Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 1 Experimental protocol for repeated treatment with sodium hyaluronate–chondroitin sulfate (HA-CS) in an animal bladder model [25]. KCl=potassium chloride; PS=protamine sulfate; s.c.=subcutaneous. European Urology Supplements 2011 10, 451-459DOI: (10.1016/j.eursup.2011.06.001) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 2 Urinary function results: bladder capacity (BC), threshold pressure (ThP), micturition pressure (MP), and bladder compliance with instillations of sodium hyaluronate–chondroitin sulfate (HA-CS) in the rat bladder model [25]. ANOVA=analysis of variance; KCl=potassium chloride; NaCl=sodium chloride; PS=protamine sulfate. European Urology Supplements 2011 10, 451-459DOI: (10.1016/j.eursup.2011.06.001) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier plot of time to recurrence of infection in patients with recurrent urinary tract infections receiving intravesical sodium hyaluronate–chondroitin sulfate (HA/CS) or placebo. Reproduced with permission from Elsevier [32]. European Urology Supplements 2011 10, 451-459DOI: (10.1016/j.eursup.2011.06.001) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 4 Urinary function parameters in patients with interstitial cystitis/painful bladder syndrome receiving intravesical sodium hyaluronate–chondroitin sulfate [2]. VAS=visual analog scale. European Urology Supplements 2011 10, 451-459DOI: (10.1016/j.eursup.2011.06.001) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 5 Quality-of-life assessments in patients with interstitial cystitis/painful bladder syndrome receiving intravesical sodium hyaluronate–chondroitin sulfate [2]. European Urology Supplements 2011 10, 451-459DOI: (10.1016/j.eursup.2011.06.001) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 6 Efficacy of intravesical sodium hyaluronate–chondroitin sulfate in 17 patients with interstitial cystitis/painful bladder syndrome, treated in a district general hospital in Reading, UK [37]. PUF=Pelvic Pain and Urinary/Frequency (score); VA=visual analog (scale score). European Urology Supplements 2011 10, 451-459DOI: (10.1016/j.eursup.2011.06.001) Copyright © 2011 European Association of Urology Terms and Conditions